Comparative barriers to molecular therapy and immunotherapy in glioblastoma: A systematic review.
- 1Department of Molecular and Medical Biotechnology, College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.
- 2Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.
- 3Department of Neurosurgery, University of Cincinnati, Cincinnati, United States.
Abstract
Background
Glioblastoma (GBM) remains refractory to molecular and immunotherapy, yet the barriers to each treatment class are often discussed together. We systematically compared the efficacy and delivery barriers reported for these approaches to clarify where their failure mechanisms overlap and diverge.Methods
A Preferred Reporting Items for Systematic reviews and Meta-Analyses-guided review of PubMed and ScienceDirect was conducted from database inception through April 4th, 2026. Eligible adult GBM studies addressing molecular therapy, immunotherapy, or both were screened and categorized by therapy type. Ten predefined barrier domains were coded as present or absent. Barrier frequencies were compared across groups using Chi-square tests, followed by Fisher's exact tests for pairwise comparisons when appropriate.Results
Eighty-two studies were included: 41 addressed both therapy classes, 34 immunotherapies only, and seven molecular therapies only. Blood-brain barrier (BBB)/blood-brain tumor barrier restriction and tumor heterogeneity were nearly universal (98.8% and 96.3%). Six barrier domains differed significantly across therapy groups. Immunosuppressive tumor microenvironment, T-cell exhaustion, low immunogenicity, and impaired central nervous system immune trafficking clustered with immunotherapy studies, whereas BBB efflux transport was concentrated in molecular therapy studies (85.7% vs. 2.9% in immunotherapy-only studies; P < 0.001). Intrinsic or adaptive resistance was universal in molecular therapy and combined-therapy studies but lower in immunotherapy-only sources (73.5%; P < 0.001).Conclusion
Molecular therapy and immunotherapy in GBM share BBB restriction and heterogeneity but fail through distinct dominant mechanisms. Combination trials should be designed around both pharmacokinetic delivery barriers and immune-microenvironmental resistance, with patient selection matched to the biology being targeted.
Related
- Large language models reveal a systematic preference in clinical immunotherapy guidelines: a multi-model comparative analysis
- Single-cell RNA sequencing combined with artificial intelligence to uncover immunotherapy biomarkers and decipher drug resistance mechanisms in glioblastoma.
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook
- Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy
- Quantitative, longitudinal measurements of response to immunotherapy for glioblastoma using multiparametric MRI in a long-term survivor treated with autologous tumor lysate-loaded dendritic cell vaccine: an illustrative case.
BibTeX
@article{salih2026comparative,
title = {{Comparative barriers to molecular therapy and immunotherapy in glioblastoma: A systematic review.}},
author = {Haneen A Salih and Ali Z Al-Saffar and Zaid Nsaif Abbas and Samer S Hoz},
journal = {Surgical neurology international},
year = {2026},
month = oct,
doi = {10.25259/sni_776_2026},
url = {https://europepmc.org/article/MED/42974574},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Comparative barriers to molecular therapy and immunotherapy in glioblastoma: A systematic review.
AU - Haneen A Salih
AU - Ali Z Al-Saffar
AU - Zaid Nsaif Abbas
AU - Samer S Hoz
PY - 2026
DA - 2026/10/02
JO - Surgical neurology international
DO - 10.25259/sni_776_2026
UR - https://europepmc.org/article/MED/42974574
AB - Background Glioblastoma (GBM) remains refractory to molecular and immunotherapy, yet the barriers to each treatment class are often discussed together. We systematically compared the efficacy and delivery barriers reported for these approaches to clarify where their failure mechanisms overlap and diverge.Methods A Preferred Reporting Items for Systematic reviews and Meta-Analyses-guided review of PubMed and ScienceDirect was conducted from database inception through April 4th, 2026. Eligible adult GBM studies addressing molecular therapy, immunotherapy, or both were screened and categorized by therapy type. Ten predefined barrier domains were coded as present or absent. Barrier frequencies were compared across groups using Chi-square tests, followed by Fisher's exact tests for pairwise comparisons when appropriate.Results Eighty-two studies were included: 41 addressed both therapy classes, 34 immunotherapies only, and seven molecular therapies only. Blood-brain barrier (BBB)/blood-brain tumor barrier restriction and tumor heterogeneity were nearly universal (98.8% and 96.3%). Six barrier domains differed significantly across therapy groups. Immunosuppressive tumor microenvironment, T-cell exhaustion, low immunogenicity, and impaired central nervous system immune trafficking clustered with immunotherapy studies, whereas BBB efflux transport was concentrated in molecular therapy studies (85.7% vs. 2.9% in immunotherapy-only studies; P < 0.001). Intrinsic or adaptive resistance was universal in molecular therapy and combined-therapy studies but lower in immunotherapy-only sources (73.5%; P < 0.001).Conclusion Molecular therapy and immunotherapy in GBM share BBB restriction and heterogeneity but fail through distinct dominant mechanisms. Combination trials should be designed around both pharmacokinetic delivery barriers and immune-microenvironmental resistance, with patient selection matched to the biology being targeted.
SN - 2229-5097
SN - 2152-7806
ER -